Differential expression of nuclear retinoid receptors in normal and malignant prostates

Yair Lotan, Xiao C. Xu, Moshe Shalev, Reuben Lotan, Russell Williams, Thomas M. Wheeler, Timothy C. Thompson, Dov Kadmon

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Purpose: To determine (1) whether nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are differentially expressed in normal and in cancerous human prostate tissues and (2) whether oral fenretinide therapy impacts the expression of these receptors in prostate cancer. Patients and Methods: In situ hybridization with antisense riboprobes was used to probe for RAR and RXR transcripts in prostate tissues in a two-phased study: (1) expression of retinoid receptors in eight normal prostates was compared with their expression in 10 randomly picked radical prostatectomy specimens (group A); (2) expression of retinoid receptors was determined in 22 radical prostatectomy specimens from participants in a clinical study (group B). Twelve patients received oral fenretinide 200 mg/d, and 10 received placebo pills for 28 days before surgery. Results: RARα, RARγ, RXRα, and RXRγ, mRNAs were detected in most normal and cancerous prostates. In group A, RARβ mRNA was expressed in only four of 10 malignant prostates but was present in seven of eight benign prostates (P = .05). RXRβ mRNA was expressed in four of eight benign prostates and in zero of 10 malignant prostates (P = .023). In group B prostates, RARβ and RXRβ mRNAs were markedly reduced in all cancers and in the adjacent, nonmalignant tissue. There were no differences between receptor expression in the fenretinide-treated group and the placebo group. Conclusion: RARβ and RXRβ mRNAs are selectively lost in both prostate cancer and adjacent morphologically normal prostatic tissue, supporting the concept of a field of carcinogenesis. One month of oral fenretinide (200 mg/d) did not influence the expression of retinoid receptors in prostate cancer.

Original languageEnglish (US)
Pages (from-to)116-121
Number of pages6
JournalJournal of Clinical Oncology
Volume18
Issue number1
StatePublished - Jan 2000

Fingerprint

Retinoids
Cytoplasmic and Nuclear Receptors
Retinoid X Receptors
Retinoic Acid Receptors
Prostate
Fenretinide
Messenger RNA
Prostatic Neoplasms
Prostatectomy
Placebos
Ambulatory Surgical Procedures
In Situ Hybridization
Carcinogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lotan, Y., Xu, X. C., Shalev, M., Lotan, R., Williams, R., Wheeler, T. M., ... Kadmon, D. (2000). Differential expression of nuclear retinoid receptors in normal and malignant prostates. Journal of Clinical Oncology, 18(1), 116-121.

Differential expression of nuclear retinoid receptors in normal and malignant prostates. / Lotan, Yair; Xu, Xiao C.; Shalev, Moshe; Lotan, Reuben; Williams, Russell; Wheeler, Thomas M.; Thompson, Timothy C.; Kadmon, Dov.

In: Journal of Clinical Oncology, Vol. 18, No. 1, 01.2000, p. 116-121.

Research output: Contribution to journalArticle

Lotan, Y, Xu, XC, Shalev, M, Lotan, R, Williams, R, Wheeler, TM, Thompson, TC & Kadmon, D 2000, 'Differential expression of nuclear retinoid receptors in normal and malignant prostates', Journal of Clinical Oncology, vol. 18, no. 1, pp. 116-121.
Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. Journal of Clinical Oncology. 2000 Jan;18(1):116-121.
Lotan, Yair ; Xu, Xiao C. ; Shalev, Moshe ; Lotan, Reuben ; Williams, Russell ; Wheeler, Thomas M. ; Thompson, Timothy C. ; Kadmon, Dov. / Differential expression of nuclear retinoid receptors in normal and malignant prostates. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 1. pp. 116-121.
@article{201e0e8f1edf49ce86e64c9d89eba3ae,
title = "Differential expression of nuclear retinoid receptors in normal and malignant prostates",
abstract = "Purpose: To determine (1) whether nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are differentially expressed in normal and in cancerous human prostate tissues and (2) whether oral fenretinide therapy impacts the expression of these receptors in prostate cancer. Patients and Methods: In situ hybridization with antisense riboprobes was used to probe for RAR and RXR transcripts in prostate tissues in a two-phased study: (1) expression of retinoid receptors in eight normal prostates was compared with their expression in 10 randomly picked radical prostatectomy specimens (group A); (2) expression of retinoid receptors was determined in 22 radical prostatectomy specimens from participants in a clinical study (group B). Twelve patients received oral fenretinide 200 mg/d, and 10 received placebo pills for 28 days before surgery. Results: RARα, RARγ, RXRα, and RXRγ, mRNAs were detected in most normal and cancerous prostates. In group A, RARβ mRNA was expressed in only four of 10 malignant prostates but was present in seven of eight benign prostates (P = .05). RXRβ mRNA was expressed in four of eight benign prostates and in zero of 10 malignant prostates (P = .023). In group B prostates, RARβ and RXRβ mRNAs were markedly reduced in all cancers and in the adjacent, nonmalignant tissue. There were no differences between receptor expression in the fenretinide-treated group and the placebo group. Conclusion: RARβ and RXRβ mRNAs are selectively lost in both prostate cancer and adjacent morphologically normal prostatic tissue, supporting the concept of a field of carcinogenesis. One month of oral fenretinide (200 mg/d) did not influence the expression of retinoid receptors in prostate cancer.",
author = "Yair Lotan and Xu, {Xiao C.} and Moshe Shalev and Reuben Lotan and Russell Williams and Wheeler, {Thomas M.} and Thompson, {Timothy C.} and Dov Kadmon",
year = "2000",
month = "1",
language = "English (US)",
volume = "18",
pages = "116--121",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Differential expression of nuclear retinoid receptors in normal and malignant prostates

AU - Lotan, Yair

AU - Xu, Xiao C.

AU - Shalev, Moshe

AU - Lotan, Reuben

AU - Williams, Russell

AU - Wheeler, Thomas M.

AU - Thompson, Timothy C.

AU - Kadmon, Dov

PY - 2000/1

Y1 - 2000/1

N2 - Purpose: To determine (1) whether nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are differentially expressed in normal and in cancerous human prostate tissues and (2) whether oral fenretinide therapy impacts the expression of these receptors in prostate cancer. Patients and Methods: In situ hybridization with antisense riboprobes was used to probe for RAR and RXR transcripts in prostate tissues in a two-phased study: (1) expression of retinoid receptors in eight normal prostates was compared with their expression in 10 randomly picked radical prostatectomy specimens (group A); (2) expression of retinoid receptors was determined in 22 radical prostatectomy specimens from participants in a clinical study (group B). Twelve patients received oral fenretinide 200 mg/d, and 10 received placebo pills for 28 days before surgery. Results: RARα, RARγ, RXRα, and RXRγ, mRNAs were detected in most normal and cancerous prostates. In group A, RARβ mRNA was expressed in only four of 10 malignant prostates but was present in seven of eight benign prostates (P = .05). RXRβ mRNA was expressed in four of eight benign prostates and in zero of 10 malignant prostates (P = .023). In group B prostates, RARβ and RXRβ mRNAs were markedly reduced in all cancers and in the adjacent, nonmalignant tissue. There were no differences between receptor expression in the fenretinide-treated group and the placebo group. Conclusion: RARβ and RXRβ mRNAs are selectively lost in both prostate cancer and adjacent morphologically normal prostatic tissue, supporting the concept of a field of carcinogenesis. One month of oral fenretinide (200 mg/d) did not influence the expression of retinoid receptors in prostate cancer.

AB - Purpose: To determine (1) whether nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are differentially expressed in normal and in cancerous human prostate tissues and (2) whether oral fenretinide therapy impacts the expression of these receptors in prostate cancer. Patients and Methods: In situ hybridization with antisense riboprobes was used to probe for RAR and RXR transcripts in prostate tissues in a two-phased study: (1) expression of retinoid receptors in eight normal prostates was compared with their expression in 10 randomly picked radical prostatectomy specimens (group A); (2) expression of retinoid receptors was determined in 22 radical prostatectomy specimens from participants in a clinical study (group B). Twelve patients received oral fenretinide 200 mg/d, and 10 received placebo pills for 28 days before surgery. Results: RARα, RARγ, RXRα, and RXRγ, mRNAs were detected in most normal and cancerous prostates. In group A, RARβ mRNA was expressed in only four of 10 malignant prostates but was present in seven of eight benign prostates (P = .05). RXRβ mRNA was expressed in four of eight benign prostates and in zero of 10 malignant prostates (P = .023). In group B prostates, RARβ and RXRβ mRNAs were markedly reduced in all cancers and in the adjacent, nonmalignant tissue. There were no differences between receptor expression in the fenretinide-treated group and the placebo group. Conclusion: RARβ and RXRβ mRNAs are selectively lost in both prostate cancer and adjacent morphologically normal prostatic tissue, supporting the concept of a field of carcinogenesis. One month of oral fenretinide (200 mg/d) did not influence the expression of retinoid receptors in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033986007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033986007&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 116

EP - 121

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -